Skip Nav Destination
Issues
15 November 2019
-
Cover Image
Cover Image
The cover shows a section from the first passage of an orthotopic xenograft from a patient-derived pancreatic cancer organoid. Masson's trichrome staining shows the deposition of collagen in blue, demonstrating that the transplantation model recapitulates the desmoplastic response observed in primary patient samples. For details, see the article by Ponz-Sarvise and colleagues on page 6742 of this issue. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
ISSN 1078-0432
EISSN 1557-3265
Highlights
CCR Translations
Reviews
Clinical Trials: Targeted Therapy
First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma
Bryan G. Allen; Kellie L. Bodeker; Mark C. Smith; Varun Monga; Sonia Sandhu; Raymond Hohl; Thomas Carlisle; Heather Brown; Nancy Hollenbeck; Sandy Vollstedt; Jeremy D. Greenlee; Matthew A. Howard; Kranti A. Mapuskar; Steven N. Seyedin; Joseph M. Caster; Karra A. Jones; Joseph J. Cullen; Daniel Berg; Brett A. Wagner; Garry R. Buettner; Mindi J. TenNapel; Brian J. Smith; Douglas R. Spitz; John M. Buatti
POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients
Richard D. Baird; Annelot G.J. van Rossum; Mafalda Oliveira; Karin Beelen; Meiling Gao; Mariette Schrier; Ingrid A.M. Mandjes; Javier Garcia-Corbacho; Anne-Laure Vallier; Greig Dougall; Erik van Werkhoven; Constanza Linossi; Sanjeev Kumar; Harm van Tinteren; Maurizio Callari; Emma Beddowes; José-Manuel Perez-Garcia; Hilde Rosing; Else Platte; Petra Nederlof; Margaret Schot; Aurelia de Vries Schultink; René Bernards; Cristina Saura; William Gallagher; Javier Cortès; Carlos Caldas; Sabine C. Linn
Evaluation of Residual Disease and TKI Duration Are Critical Predictive Factors for Molecular Recurrence after Stopping Imatinib First-line in Chronic Phase CML Patients
Franck Emmanuel Nicolini; Stéphanie Dulucq; Lisa Boureau; Pascale Cony-Makhoul; Aude Charbonnier; Martine Escoffre-Barbe; Françoise Rigal-Huguet; Valérie Coiteux; Bruno Varet; Viviane Dubruille; Pascal Lenain; Philippe Rousselot; Delphine Rea; Agnès Guerci-Bresler; Laurence Legros; Jixing Liu; Martine Gardembas; Jean-Christophe Ianotto; Pascal Turlure; Hyacinthe Johnson-Ansah; Juliana Martiniuc; Henry Jardel; Bertrand Joly; Patricia Zunic; Tawfiq Henni; Bruno Villemagne; Marc G. Berger; Emilie Cayssials; François Guilhot; Fabrice Larosa; Joëlle Guilhot; Gabriel Etienne; François-Xavier Mahon
Clinical Trials: Immunotherapy
A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors
Toshihiko Doi; Kei Muro; Hiroshi Ishii; Terufumi Kato; Takahiro Tsushima; Mitsuhiro Takenoyama; Satoshi Oizumi; Kazuto Gemmoto; Hideaki Suna; Kouki Enokitani; Tetsuyoshi Kawakami; Hiroyoshi Nishikawa; Noboru Yamamoto
Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
Jhanelle E. Gray; Andreas Saltos; Tawee Tanvetyanon; Eric B. Haura; Ben Creelan; Scott J. Antonia; Michael Shafique; Hong Zheng; Wenjie Dai; James J. Saller; Zhihua Chen; Nishan Tchekmedyian; Kristen Goas; Ram Thapa; Theresa A. Boyle; Dung-Tsa Chen; Amer A. Beg
Precision Medicine and Imaging
Dose Optimization for Anticancer Drug Combinations: Maximizing Therapeutic Index via Clinical Exposure-Toxicity/Preclinical Exposure-Efficacy Modeling
Dean C. Bottino; Mayankbhai Patel; Ekta Kadakia; Jilai Zhou; Chirag Patel; Rachel Neuwirth; Natasha Iartchouk; Rachael Brake; Karthik Venkatakrishnan; Arijit Chakravarty
Tissue and Plasma EGFR Mutation Analysis in the FLAURA Trial: Osimertinib versus Comparator EGFR Tyrosine Kinase Inhibitor as First-Line Treatment in Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer
Jhanelle E. Gray; Isamu Okamoto; Virote Sriuranpong; Johan Vansteenkiste; Fumio Imamura; Jong Seok Lee; Yong-Kek Pang; Manuel Cobo; Kazuo Kasahara; Ying Cheng; Naoyuki Nogami; Eun Kyung Cho; Wu Chou Su; Guili Zhang; Xiangning Huang; Xiaocheng Li-Sucholeiki; Brian Lentrichia; Simon Dearden; Suzanne Jenkins; Matilde Saggese; Yuri Rukazenkov; Suresh S. Ramalingam
Author Choice
Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity
Ibiayi Dagogo-Jack; Marguerite Rooney; Jessica J. Lin; Rebecca J. Nagy; Beow Y. Yeap; Harper Hubbeling; Emily Chin; Jennifer Ackil; Anna F. Farago; Aaron N. Hata; Jochen K. Lennerz; Justin F. Gainor; Richard B. Lanman; Alice T. Shaw
Author Choice
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non–Small-Cell Lung Cancer
Emma Pailler; Vincent Faugeroux; Marianne Oulhen; Laura Mezquita; Mélanie Laporte; Aurélie Honoré; Yann Lecluse; Pauline Queffelec; Maud NgoCamus; Claudio Nicotra; Jordi Remon; Ludovic Lacroix; David Planchard; Luc Friboulet; Benjamin Besse; Françoise Farace
Tumor Growth Rate as a Validated Early Radiological Biomarker Able to Reflect Treatment-Induced Changes in Neuroendocrine Tumors: The GREPONET-2 Study
Angela Lamarca; Maxime Ronot; Salma Moalla; Joakim Crona; Marta Opalinska; Carlos Lopez Lopez; Daniela Pezzutti; Pavan Najran; Luciana Carvhalo; Regis Otaviano Franca Bezerra; Philip Borg; Naik Vietti Violi; Hector Vidal Trueba; Louis de Mestier; Niklaus Scaefer; Eric Baudin; Anders Sundin; Frederico Costa; Marianne Pavel; Clarisse Dromain
Whole–Genome Sequencing of Childhood Cancer Survivors Treated with Cranial Radiation Therapy Identifies 5p15.33 Locus for Stroke: A Report from the St. Jude Lifetime Cohort Study
Yadav Sapkota; Yin Ting Cheung; Wonjong Moon; Kyla Shelton; Carmen L. Wilson; Zhaoming Wang; Daniel A. Mulrooney; Jinghui Zhang; Gregory T. Armstrong; Melissa M. Hudson; Leslie L. Robison; Kevin R. Krull; Yutaka Yasui
Translational Cancer Mechanisms and Therapy
An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors
Rui Wang; Chan Gao; Megan Raymond; Gennaro Dito; Dominic Kabbabe; Xiao Shao; Ed Hilt; Yongliang Sun; Irene Pak; Martin Gutierrez; Ignacio Melero; Anna Spreafico; Richard D. Carvajal; Michael Ong; Anthony J. Olszanski; Christina Milburn; Kent Thudium; Zheng Yang; Yan Feng; Paula M. Fracasso; Alan J. Korman; Praveen Aanur; Shih-Min A. Huang; Michael Quigley
Transcriptomic Heterogeneity of Androgen Receptor Activity Defines a de novo low AR-Active Subclass in Treatment Naïve Primary Prostate Cancer
Daniel E. Spratt; Mohammed Alshalalfa; Nick Fishbane; Adam B. Weiner; Rohit Mehra; Brandon A. Mahal; Jonathan Lehrer; Yang Liu; Shuang G. Zhao; Corey Speers; Todd M. Morgan; Adam P. Dicker; Stephen J. Freedland; R. Jeffery Karnes; Sheila Weinmann; Elai Davicioni; Ashley E. Ross; Robert B. Den; Paul L. Nguyen; Felix Y. Feng; Tamara L. Lotan; Arul M. Chinnaiyan; Edward M. Schaeffer
Interaction between Molecular Subtypes and Stromal Immune Infiltration before and after Treatment in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
Anne-Sophie Hamy; Hélène Bonsang-Kitzis; Diane De Croze; Enora Laas; Lauren Darrigues; Lucian Topciu; Emmanuelle Menet; Anne Vincent-Salomon; Florence Lerebours; Jean-Yves Pierga; Etienne Brain; Jean-Guillaume Feron; Gabriel Benchimol; Giang-Thanh Lam; Marick Laé; Fabien Reyal
Identification of Resistance Pathways Specific to Malignancy Using Organoid Models of Pancreatic Cancer
Mariano Ponz-Sarvise; Vincenzo Corbo; Hervé Tiriac; Dannielle D. Engle; Kristopher K. Frese; Tobiloba E. Oni; Chang-Il Hwang; Daniel Öhlund; Iok In Christine Chio; Lindsey A. Baker; Dea Filippini; Kevin Wright; Tashinga E. Bapiro; Pearl Huang; Paul Smith; Kenneth H. Yu; Duncan I. Jodrell; Youngkyu Park; David A. Tuveson
CD45+CD326+ Cells are Predictive of Poor Prognosis in Non–Small Cell Lung Cancer Patients
Kota Ishizawa; Mie Yamanaka; Yuriko Saiki; Eisaku Miyauchi; Shinichi Fukushige; Tetsuya Akaishi; Atsuko Asao; Takahiro Mimori; Ryota Saito; Yutaka Tojo; Riu Yamashita; Michiaki Abe; Akira Sakurada; Nhu-An Pham; Ming Li; Yoshinori Okada; Tadashi Ishii; Naoto Ishii; Seiichi Kobayashi; Masao Nagasaki; Masakazu Ichinose; Ming-Sound Tsao; Akira Horii
Orally Bioavailable Androgen Receptor Degrader, Potential Next-Generation Therapeutic for Enzalutamide-Resistant Prostate Cancer
Suriyan Ponnusamy; Yali He; Dong-Jin Hwang; Thirumagal Thiyagarajan; Rene Houtman; Vera Bocharova; Bobby G. Sumpter; Elias Fernandez; Daniel Johnson; Ziyun Du; Lawrence M. Pfeffer; Robert H. Getzenberg; Iain J. McEwan; Duane D. Miller; Ramesh Narayanan
Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis
Neeraj Saini; Junsheng Ma; Denái R. Milton; Romil Patel; Ankur Varma; Qaiser Bashir; Ruby Delgado; Akash Mukherjee; Gabriela Rondon; Uday R. Popat; Chitra M. Hosing; Yago Nieto; Partow Kebriaei; Amin M. Alousi; Sairah Ahmed; Guilin Tang; Rohtesh Mehta; Samer Srour; Issa F. Khouri; Swaminathan Iyer; Donna M. Weber; Sheeba K. Thomas; Hans C. Lee; Elisabet E. Manasanch; Krina K. Patel; Robert Z. Orlowski; Richard E. Champlin; Muzaffar H. Qazilbash
TP53 Pathway Alterations Drive Radioresistance in Diffuse Intrinsic Pontine Gliomas (DIPG)
Coralie Werbrouck; Cláudia C.S. Evangelista; María-Jesús Lobón-Iglesias; Emilie Barret; Gwénaël Le Teuff; Jane Merlevede; Romain Brusini; Thomas Kergrohen; Michele Mondini; Stéphanie Bolle; Pascale Varlet; Kevin Beccaria; Nathalie Boddaert; Stéphanie Puget; Jacques Grill; Marie-Anne Debily; David Castel
Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas
Hong Jiang; Dong Ho Shin; Teresa T. Nguyen; Juan Fueyo; Xuejun Fan; Verlene Henry; Caroline C. Carrillo; Yanhua Yi; Marta M. Alonso; Tiara L. Collier; Ying Yuan; Frederick F. Lang; Candelaria Gomez-Manzano
Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia
Jun Ma; Shoujing Zhao; Xinan Qiao; Tristan Knight; Holly Edwards; Lisa Polin; Juiwanna Kushner; Sijana H. Dzinic; Kathryn White; Guan Wang; Lijing Zhao; Hai Lin; Yue Wang; Jeffrey W. Taub; Yubin Ge
TFEB Mediates Immune Evasion and Resistance to mTOR Inhibition of Renal Cell Carcinoma via Induction of PD-L1
Cai Zhang; Yaqi Duan; Minghui Xia; Yuting Dong; Yufei Chen; Lu Zheng; Shuaishuai Chai; Qian Zhang; Zhengping Wei; Na Liu; Jing Wang; Chaoyang Sun; Zhaohui Tang; Xiang Cheng; Jie Wu; Guoping Wang; Fang Zheng; Arian Laurence; Bing Li; Xiang-Ping Yang
PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer
Bo Liu; Likun Li; Guang Yang; Chuandong Geng; Yong Luo; Wenhui Wu; Ganiraju C. Manyam; Dimitrios Korentzelos; Sanghee Park; Zhe Tang; Cheng Wu; Zhenyang Dong; Michael Sigouros; Andrea Sboner; Himisha Beltran; Yu Chen; Paul G. Corn; Michael T. Tetzlaff; Patricia Troncoso; Bradley Broom; Timothy C. Thompson
A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors
Andrea Aloia; Daniela Müllhaupt; Christophe D. Chabbert; Tanja Eberhart; Stefanie Flückiger-Mangual; Ana Vukolic; Ossia Eichhoff; Anja Irmisch; Leila T. Alexander; Ernesto Scibona; Dennie T. Frederick; Benchun Miao; Tian Tian; Chaoran Cheng; Lawrence N. Kwong; Zhi Wei; Ryan J. Sullivan; Genevieve M. Boland; Meenhard Herlyn; Keith T. Flaherty; Nicola Zamboni; Reinhard Dummer; Gao Zhang; Mitchell P. Levesque; Wilhelm Krek; Werner J. Kovacs
Author Choice
Long Noncoding RNA SChLAP1 Forms a Growth-Promoting Complex with HNRNPL in Human Glioblastoma through Stabilization of ACTN4 and Activation of NF-κB Signaling
Jianxiong Ji; Ran Xu; Kaikai Ding; Guoqing Bao; Xin Zhang; Bin Huang; Xinyu Wang; Aurora Martinez; Xiuying Wang; Gang Li; Hrvoje Miletic; Frits Thorsen; Rolf Bjerkvig; Lei Xiang; Bo Han; Anjing Chen; Xingang Li; Jian Wang
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale within the United States of Bavencio® (avelumab), a pharmaceutical owned by Merck. If any resulting funds are received, they would not be used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds